Michael Gelband’s Mirum Pharmaceuticals MIRM Stock Holding History

Michael Gelband’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-87,373	Closed	-$8.07M	–	1873
2026 Q1	$8.07M	Buy	+87,373	New	+$8.22M	0.06%	290
2025 Q3	–	Sell	-34,175	Closed	-$1.74M	–	1836
2025 Q2	$1.74M	Sell	34,175 -2,087	-6%	-$92.9K	0.02%	794
2025 Q1	$1.63M	Buy	36,262 +14,109	+64%	+$665K	0.02%	767
2024 Q4	$916K	Buy	+22,153	New	+$923K	0.01%	971
2024 Q3	–	Sell	-43,747	Closed	-$1.5M	–	1903
2024 Q2	$1.5M	Sell	43,747 -20,672	-32%	-$542K	0.01%	887
2024 Q1	$1.62M	Buy	64,419 +31,237	+94%	+$859K	0.01%	786
2023 Q4	$980K	Buy	+33,182	New	+$1M	0.01%	828
2022 Q1	–	Sell	-52,474	Closed	-$837K	–	2490
2021 Q4	$837K	Buy	52,474 +25,221	+93%	+$392K	0.01%	1165
2021 Q3	$543K	Buy	+27,253	New	+$443K	0.01%	1331
2021 Q2	–	Sell	-14,570	Closed	-$289K	–	2630
2021 Q1	$289K	Buy	+14,570	New	+$279K	﹤0.01%	1702
2020 Q3	–	Sell	-17,600	Closed	-$342K	–	2044
2020 Q2	$342K	Buy	+17,600	New	+$294K	0.01%	1250

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's MIRM Position: Q2 2026 in Review

Michael Gelband sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 87,373 shares — an estimated $8.07M sold.

Michael Gelband first reported a position in MIRM in Q2 2020 and held it in 11 quarters. The position peaked at $8.07M in Q1 2026. 326 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Michael Gelband reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 87,373 Mirum Pharmaceuticals shares in Q2 2026, an estimated $8.07M.
Michael Gelband first reported a position in Mirum Pharmaceuticals in Q2 2020 and held it in 11 quarters.
Michael Gelband's Mirum Pharmaceuticals position peaked at $8.07M in Q1 2026.
326 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.